---
title: "treatment of multiple myeloma (MM)"
slug: "treatment-of-multiple-myeloma-mm"
date: "2023-05-26"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[treatment and prognosis of multiple myeloma (MM)]]

# treatment of multiple myeloma (MM)

## News: 


[[isatuximab.md|Isatuximab]] 2024-06-04



---


- incl. proteasome inhibitors:
  - **bortezomib (V)**
  - carfilzomib (K)
  - ixazomib (I);
- immunomodulators:
  - **lenalidomide (R)**
  - thalidomide (T),
  - pomalidomide (P);
- immunotherapy:
  - daratumumab (anti-CD38, Dara),
  - elotuzumab (anti-SLAMF7, Elo)
- Other active drugs:
  - **dexamethasone (D)**
  - melphalan,
  - panobinostat,
  - cyclophosphamide

## Induction Rx w/ best response rate

- proteasome inhib (V or K) + immunomod (eg, R).
- Triplet Rx â†‘ OS vs. double (Lancet 2017;389:519).
- RVD most common regimen in US;
- KRD if high-risk (NEJM 2014;371:906 & 2016;374:1621).
- Dara-RD an option (NEJM 2019;380:2104).
- Quad Rx (Dara-RVD) may improve response rates (Blood 2020;136:936).

- [[If not transplant eligible-of-treatment of multiple myeloma]] (MM)
- [[If transplant eligible-of-treatment of multiple myeloma]] (MM)
